Drugs / FDG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00963807 | Sep 2009 → Aug 2012 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FDG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00963807 ↗ |
| Modality | Diagnostic / imaging agent | “FDG is used routinely in the staging of lung cancer and is approved by the FDA for that purpose.” NCT00963807 ↗ |